Insider · CIK 0001961994
Paul Anthony Williams
Files at EBS (Emergent BioSolutions Inc.). First filing Apr 3, 2026, latest Oct 5, 2026.
In brief
Paul Anthony Williams files SEC Form 4 as officer at EBS (Emergent BioSolutions Inc.). Since Apr 3, 2026, Paul Anthony Williams has reported 0 open-market buys worth $0 and 3 open-market sells worth $79k, the latest filed on Oct 5, 2026.
A track record needs three past buys with six months of prices behind them; Paul Anthony Williams has 0, so none is measured yet.
The newest scored trade: sold $20k of EBS on Oct 1, 2026, filed Oct 5, 2026, scored 3 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $79k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EBS: Emergent BioSolutions Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Emergent BioSolutions Inc. | $20k 3,000 shares | -2% | +43% from low-54% from high | |
| 0Weak | Emergent BioSolutions Inc. | $25k 3,000 shares | -2% | +47% from low-40% from high | |
| 1Weak | Emergent BioSolutions Inc. | $34k 4,000 shares | -6% | +97% from low-40% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 1, 2026 | EBS EMERGENT BIOSOLUTIONS INC. | 3,000 0.01% of outstanding | $20k | Oct 1, 2026 | none |
| Jul 1, 2026 | EBS EMERGENT BIOSOLUTIONS INC. | 3,000 0.01% of outstanding | $25k | Jul 1, 2026 | none |
| Apr 1, 2026 | EBS EMERGENT BIOSOLUTIONS INC. | 4,000 0.01% of outstanding | $34k | Apr 1, 2026 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock10b5-1 | -3,000 | $6.53 | $20k | 156,098 | 9 d ago |
| Jul 1, 2026 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock10b5-1 | -3,000 | $8.40 | $25k | 159,098 | Jul 2, 2026 |
| Jun 8, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -694 | $8.00 | $5,552 | 162,098 | Jun 10, 2026 |
| Apr 29, 2026 | EBS Emergent BioSolutions Inc. | AGrant or award Common Stock | +100,111 | $0.00 | $0 | 162,792 | May 1, 2026 |
| Apr 1, 2026 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock10b5-1 | -4,000 | $8.44 | $34k | 62,681 | Apr 3, 2026 |
| Mar 5, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -9,397 | $8.44 | $79k | 66,681 | Mar 5, 2026 |
| Mar 3, 2026 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Option (Right to buy)derivative | +44,834 | $0.00 | $0 | 254,948 | Mar 5, 2026 |
| Mar 1, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -116 | $8.15 | $945 | 76,078 | Mar 3, 2026 |
| Feb 6, 2026 | EBS Emergent BioSolutions Inc. | DDisposition to issuer Common Stock | -8,655 | $10.92 | $95k | 77,216 | Feb 10, 2026 |
| Feb 6, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -1,022 | $10.92 | $11k | 76,194 | Feb 10, 2026 |
| Jun 8, 2025 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -464 | $6.63 | $3,076 | 85,871 | Jun 10, 2025 |
| Mar 6, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 86,335 | Mar 10, 2025 |
| Mar 6, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Options (Right to Buy)derivative | +62,500 | $0.00 | $0 | 210,114 | Mar 10, 2025 |
| Feb 28, 2025 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -382 | $7.48 | $2,857 | 23,951 | Mar 4, 2025 |
| Mar 1, 2025 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -116 | $7.48 | $868 | 23,835 | Mar 4, 2025 |
| Mar 13, 2024 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Options (Right to Buy)derivative | +125,000 | $0.00 | $0 | 147,614 | Mar 15, 2024 |
| Feb 29, 2024 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -450 | $3.23 | $1,454 | 25,019 | Mar 4, 2024 |
| Mar 1, 2024 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -137 | $3.39 | $464 | 24,882 | Mar 4, 2024 |
| Feb 23, 2024 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -105 | $2.74 | $288 | 25,469 | Feb 27, 2024 |
| Nov 13, 2023 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -566 | $1.82 | $1,030 | 25,574 | Nov 14, 2023 |
Questions about Paul Anthony Williams
Answered from the filings on this page, as of the latest one.
Is Paul Anthony Williams buying or selling?
In the last 12 months Paul Anthony Williams reported 0 open-market buys worth $0 and 3 open-market sells worth $79k on SEC Form 4; the latest was sold $20k of EBS on Oct 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Paul Anthony Williams's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul Anthony Williams has 0.
Where does Paul Anthony Williams file Form 4?
Paul Anthony Williams has filed Form 4 at EBS (Emergent BioSolutions Inc.) as SVP, Products Business. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.